title: The influence of octreotide treatment on pulsatile growth hormone release in acromegaly.
abstract: The pulsatile release of GH was investigated in eight active acromegalic patients before and during a subcutaneous infusion of 300 micrograms octreotide/24 h for 4 weeks. The number of GH pulses increased from a basal value of 14.4/24h to 16.3/24h during octreotide therapy. At the same time the mean GH concentration, valley concentration, peak height and amplitude decreased significantly. The inhibitory effect of octreotide on pulse characteristics did not depend on the time of day. IGF-I levels also decreased significantly; in five patients normal levels were reached. IGF-I levels correlated significantly with the mean GH level (r = 0.714, P less than 0.001), mean valley concentration (r = 0.697, P less than 0.001) and, to a lesser extent, area under the curve (r = 0.436, P = 0.033), but not the number of pulses. Plasma octreotide levels did not correlate with pulse parameters. In all but one patient a circadian rhythm was present during both the basal study and octreotide therapy. Compared with surgically treated acromegalics, the number of GH pulses was higher in untreated and octreotide-treated patients. This study demonstrates the pulsatile release of GH in active acromegaly both before and during octreotide therapy. This result suggests that endogenous GHRH is important for the generation of GH pulses in this disease.
authors.affiliation: Department of Endocrinology, University Hospital, Leiden, The Netherlands.
authors.forename: F
authors.initials: F
authors.lastname: Roelfsema
authors.forename: H
authors.initials: H
authors.lastname: de Boer
authors.forename: M
authors.initials: M
authors.lastname: Frölich
mesh_terms: D000172:Acromegaly / Q000097:blood* / Q000188:drug therapy; D000328:Adult; D000368:Aged; D002940:Circadian Rhythm / Q000502:physiology; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*
chemical_list: D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide